Corpus overview


Overview

MeSH Disease

Human Phenotype

There are no HP terms in the subcorpus


Transmission

Seroprevalence

There are no seroprevalence terms in the subcorpus

    displaying 1 - 1 records in total 1
    records per page




    Clinical features and sexual transmission TRANS potential of SARS-CoV-2 infected female TRANS patients: a descriptive study in Wuhan, China

    Authors: Pengfei Cui; Zhe Chen; Tian Wang; Jun Dai; Jinjin Zhang; Ting Ding; Jingjing Jiang; Jia Liu; Cong Zhang; Wanying Shan; Sheng Wang; Yueguang Rong; Jiang Chang; Xiaoping Miao; Xiangyi Ma; Shixuan Wang

    doi:10.1101/2020.02.26.20028225 Date: 2020-02-27 Source: medRxiv

    Background: As of March 2, 2020, SARS-CoV-2 has infected more than 80174 people and caused 2915 deaths MESHD in China. This virus rapidly spreads to 56 countries worldwide. Thus, in order to effectively block its transmission TRANS, it is urgent to uncover all the possible transmission TRANS routes of SARS-CoV-2. Methods: From January 28 to February 18, 2020, 35 female TRANS patients diagnosed with COVID-19 in Tongji Hospital were included in this descriptive study. The gynecologic history, clinical characteristics, laboratory findings and chest computed tomography (CT) of all patients were recorded in detail. To examine whether there is sexual transmission TRANS through vaginal from female TRANS to her partner, we employed real-time polymerase chain reaction testing (RT-PCR) to detect SARS-CoV-2 in vaginal environment (including vaginal discharge MESHD, cervical or vaginal residual exfoliated cells) and anal swab samples, and inquired recent sexual behaviors from the patients. Findings: The age TRANS range of the 35 patients with COVID-19 was 37-88 years. Over 50% patients infected with SARS-CoV-2 had chronic diseases MESHD. We tested the vaginal environment and anal swabs from the 35 female TRANS patients with COVID-19 and found that only an anal swab sample from one patient was positive for SARS-CoV-2. All the samples from vaginal environment were negative for SARS-CoV-2. The infection MESHD rate of the patients' sexual partner was 42.9%. Additionally, two female TRANS patients admitted having sex with their partners during a possible infection MESHD incubation period TRANS, while one patient's partner was uninfected and the other patient's partner was diagnosed with COVID-19 (after the diagnosis of the female TRANS patient). Conclusion: No positive RT-PCR result was found in the vaginal environment perhaps due to the lack of ACE2 expression, which is the receptor of SARS-CoV-2, in the vagina and cervix tissues (human protein atlas). The results from this study show no evidence of transmission TRANS of SARS-CoV-2 through vaginal sex from female TRANS to her partner. However, the risk of infection TRANS risk of infection TRANS infection MESHD of non vaginal sex and other intimate contacts during vaginal sex should not be ignored.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.